ScionxBio

ScionxBio, formerly Eleven Therapeutics, is a biotechnology company developing xRNA, a chemically expanded RNA modality engineered to extend protein expression from days to months.

Combinatorial chemistry and deep learning are combined to design molecules with enhanced stability and reduced immune sensing, enabling infrequent dosing.

The company's initial focus is cardio-metabolic disease, where it is developing programmable combinations of RNA payloads intended to act on multiple disease-driving pathways at once.